Arrhythmias & electrophysiologyRandomised controlled trial
Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial
- Randomised controlled trial
- prospective
- single-centre
- randomized (2:1)
- prematurely terminated
Enrolment September 2017; prematurely terminated February 2024
Authors' conclusion
Epicardial catheter ablation was associated with a reduction in VF recurrence compared with ICD therapy alone.
Study context
- Population
- High-risk Brugada syndrome patients with cardiac arrest or appropriate ICD therapies, all with an ICD
- Participants
- 40 patients
- Comparison
- Epicardial ablation vs no ablation
- Ablationn = 26
- Controln = 14reference
- Primary endpoint
- Freedom from ventricular fibrillation (VF) recurrences
- Follow-up
- Mean 4.0 ± 1.7 years
Primary result
As reported in the abstract
Freedom from VF recurrence
P < 0.001
Secondary outcomes
Unexplained or arrhythmic deaths
- No unexplained or arrhythmic deaths during follow-up
Safety
| Outcome | Ablation | Control |
|---|---|---|
| Post-procedural pericardial effusion requiring pericardiocentesis | 1 events | Not reported in the abstract |
Major ICD-related complications
- Major ICD-related complications (all patients)
- 13 (33%)
Original publication
Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial. Europace. Published 22 May 2025. doi:10.1093/europace/euaf097
Summarised from the published abstract; every number is checked against it